{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:58:22Z","timestamp":1777859902942,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2009,7,17]],"date-time":"2009-07-17T00:00:00Z","timestamp":1247788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Renin Angiotensin Aldosterone Syst"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p>Introduction. This subgroup analysis assessed the effects of treatment based on the direct renin inhibitor, aliskiren, or the angiotensin-converting enzyme inhibitor, ramipril, on plasma renin activity (PRA), plasma renin concentration (PRC) and other biomarkers in a 26-week randomised, double-blind trial. Changes in PRA and PRC after stopping treatment were also assessed.<\/jats:p>\n                  <jats:p>Methods. After placebo run-in, 842 patients (mean sitting diastolic blood pressure (BP) 95\u2014109 mmHg) were randomised to aliskiren 150 mg or ramipril 5 mg. Dose titration and hydrochlorothiazide addition were allowed after Week 6 and 12, respectively, for inadequate BP control. Patients completing active treatment were re-randomised to current regimen or placebo during a 4-week posttreatment phase.<\/jats:p>\n                  <jats:p>Results. BP reductions were independent of baseline PRA at Week 12, were greater with aliskiren- than ramipril-based therapy at Week 26 (17.9\/13.3 vs. 15.2\/12.0 mmHg, p&lt;0.05) and persisted for longer after stopping aliskiren. Aliskiren-based therapy reduced geometric mean PRA (\u221263%, p&lt;0.05; n=103), while ramipril-based therapy increased PRA (+143%, p&lt;0.05; n=100) at Week 26; PRC increased in both groups (aliskiren: +224% [n=33], ramipril: +145% [n=39], both p&lt;0.05). Four weeks after stopping aliskiren-based therapy, PRA remained 52% below pre-treatment baseline; PRA returned to baseline 2 weeks after stopping ramipril-based therapy.<\/jats:p>\n                  <jats:p>Conclusions. Aliskiren-based therapy produced sustained BP and PRA reductions over 26 weeks; ramipril-based therapy lowered BP and increased PRA. PRA reductions persisted 4 weeks after stopping aliskiren, suggesting an inhibitory effect beyond the elimination half-life of the drug.<\/jats:p>","DOI":"10.1177\/1470320309342407","type":"journal-article","created":{"date-parts":[[2009,7,17]],"date-time":"2009-07-17T20:50:24Z","timestamp":1247863824000},"page":"157-167","source":"Crossref","is-referenced-by-count":35,"title":["Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension"],"prefix":"10.1177","volume":"10","author":[{"given":"Karl","family":"Andersen","sequence":"first","affiliation":[{"name":"University of Iceland, Reykjavik, Iceland,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron H","family":"Weinberger","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN, USA, MaisonneuveRosemont Hospital, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian M","family":"Constance","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN, USA, MaisonneuveRosemont Hospital, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A","family":"Ali","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Jin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret F","family":"Prescott","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L","family":"Keefe","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,7,17]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-120-30547"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000131449.94713.AD"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.32.3.387"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199002000-00015"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1007\/BF02938391"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.11.032"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3280103a6b"},{"key":"atypb8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehi649","volume":"27","author":"Pool JL","year":"2006","journal-title":"Eur Heart J"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000146686.35541.29"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61124-6"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.106.084301"},{"issue":"18","key":"atypb12","first-page":"773","volume":"114","author":"Gradman AH","year":"2006","journal-title":"Circulation"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2007.028"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2003.10.030"},{"issue":"1","key":"atypb15","first-page":"393","volume":"29","author":"Vergaro G.","year":"2008","journal-title":"Eur Heart J"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000242176.36953.f7"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282f3ad9a"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000156466.02908.ED"},{"key":"atypb20","first-page":"S3","volume":"10","author":"Lees KR","year":"1992","journal-title":"J Hypertens"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198511000-00023"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000209989.59230.2e"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01473.x"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282ef45e9"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.109967"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.108845"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.123042"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2007.04.001"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2003.08.015"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.01.092"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-005-0222-5"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-200510000-00002"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000226046.58883.32"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708379"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.68"}],"container-title":["Journal of the Renin-Angiotensin-Aldosterone System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1470320309342407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1470320309342407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:39:41Z","timestamp":1777509581000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1470320309342407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,17]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1177\/1470320309342407"],"URL":"https:\/\/doi.org\/10.1177\/1470320309342407","relation":{},"ISSN":["1470-3203","1752-8976"],"issn-type":[{"value":"1470-3203","type":"print"},{"value":"1752-8976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,17]]}}}